Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) will participate in the AATS 106th Annual Meeting May 2–5 in Chicago and attend the ERAS Cardiac Spring Retreat. The company will showcase its Aquadex SmartFlow ultrafiltration system for fluid removal at Booth 530 and engage with cardiac surgery thought leaders.
Positive
- None.
Negative
- None.
News Market Reaction – NUWE
In the Apr 23 session, NUWE gained 3.89%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | Product update | Positive | -0.9% | Aquadex software update to enhance precision and usability, especially pediatrics. |
| Apr 16 | Hiring / staffing | Positive | -2.9% | Return of three commercial and clinical team members to support Aquadex growth. |
| Apr 9 | IR engagement | Positive | +0.0% | Engagement of CORE IR to expand market awareness and communications. |
| Apr 7 | Territory expansion | Positive | +3.7% | Creation of South Texas commercial territory to expand Aquadex access. |
| Mar 31 | Pediatric segment update | Positive | +0.0% | Pediatric category reaching ~50% of U.S. revenue and 47 centers footprint. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent operational and commercial updates have often seen muted or negative 24-hour price reactions, even when news skewed operationally positive.
Over the past month, Nuwellis has focused on commercial expansion and product refinement. Updates included a software enhancement for the Aquadex platform on Apr 21, rehiring experienced commercial and clinical staff on Apr 16, and creating a dedicated South Texas territory on Apr 7. A pediatric revenue milestone was reported on Mar 31. Today’s conference participation news continues this theme of building visibility and utilization for Aquadex rather than introducing new financial data.
Key Terms
ultrafiltration medical
cardiorenal medical
cardiothoracic medical
perioperative medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530
MINNEAPOLIS, April 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will participate in the AATS 106th Annual Meeting taking place May 2–5 in Chicago. The Company will be showcasing its Aquadex SmartFlow® ultrafiltration system for fluid removal at Booth 530. At the start of the event, Nuwellis will attend the ERAS Cardiac Spring Retreat gathering of thought leaders, to discuss best practices and innovation in cardiac surgery care.
“AATS is one of the largest congresses in the cardiothoracic arena, and a unique opportunity to showcase our Aquadex technology, and discuss new updates, including ongoing advancements in precision ultrafiltration therapy,” said Nuwellls’ CEO John Erb. “At the ERAS Cardiac retreat, experts and thought leaders will discuss key issues facing practitioners today. Inclusion in this event is an important opportunity for Nuwellis to connect with industry colleagues in a lively dialogue, and we look forward to our annual participation.”
The AATS 106th Annual Meeting is a premier cardiothoracic surgery event, bringing together leading experts from around the world to share best practices, explore cutting-edge innovations, and advance the field. ERAS Cardiac is a nonprofit organization focused on enhancing perioperative care in adult cardiac surgery.
For more information on the AATS 106th Annual Meeting, visit the event’s website.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
